Syndopa CR
✅ Effective in Parkinson’s
✅ Extended release formula
✅ Reduces motor symptoms
✅ Improves quality of life
Syndopa CR contains Levodopa and Carbidopa.
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
⚡ Quick Answer
Syndopa CR este un controlled-release combination tablet of levodopa + carbidopa (125 mg (100 mg levodopa + 25 mg carbidopa, controlled-release)) — the cornerstone treatment for Parkinson disease. Levodopa is converted to dopamine in the brain to replace what failing nigral neurones can no longer make; carbidopa blocks that conversion outside the brain so more levodopa reaches the central nervous system, with fewer peripheral side effects (nausea, vomiting, postural drops). CR formulation reduces “wearing-off” between doses and is particularly useful at bedtime to manage overnight stiffness and early-morning akinesia. CR bioavailability is about 70–75% of IR, so the effective dose is slightly lower than IR — an IR “top-up” on waking is often added to break early-morning akinesia rapidly. Critical: never stop levodopa abruptly — risk of neuroleptic malignant-like syndrome. Dose must be tapered.
📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.
De ce să comanzi de la MedsBase
Medicamentele noastre generice sunt procurate de la producători certificați WHO-GMP și expediate la nivel mondial în ambalaje discrete și simple — fără denumirea medicamentului pe exteriorul coletului. Plățile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de plăți cu card reglementat — niciodată “MedsBase” sau numele vreunui medicament). Acceptăm și criptomonede și transferuri bancare SEPA. Fiecare comandă este susținută de Politica noastră de Asigurare pentru Relivrare.
What Is Syndopa CR?
Syndopa CR is an oral tablet containing levodopa + carbidopa 125 mg (100 mg levodopa + 25 mg carbidopa, controlled-release) într-o controlled-release formulation. The combination has been the foundation of Parkinson disease therapy since the 1970s and remains the most effective single treatment for motor symptoms (bradykinesia, rigidity, tremor). It was originally marketed as Sinemet / Sinemet CR. Syndopa CR is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.
How Does Syndopa CR Work?
Parkinson disease results from progressive loss of dopamine-producing neurones in the substantia nigra. Levodopa is the immediate biochemical precursor of dopamine; unlike dopamine itself, it crosses the blood–brain barrier. Once inside the brain, surviving neurones decarboxylate it to dopamine, restoring synaptic dopamine levels and improving motor control.
The problem: when levodopa is given alone, >95% is converted to dopamine in peripheral tissues before it reaches the brain — causing severe nausea, vomiting and orthostatic hypotension, and forcing the use of huge doses. Carbidopa is a peripheral aromatic-amino-acid decarboxylase inhibitor. It does not cross the blood–brain barrier itself, but blocks the breakdown of levodopa in peripheral tissues. The result: a 4–5-fold reduction in the levodopa dose needed for the same brain effect, and far fewer GI/cardiovascular side effects.
Numele controlled-release matrix slows tablet dissolution so levodopa is absorbed over 4–6 hours rather than 1–2. This smooths plasma levels and helps reduce end-of-dose wearing-off in patients with motor fluctuations. The trade-off: bioavailability is about 70–75% of the IR tablet, so the effective dose is slightly lower; food (especially protein) further delays absorption. Many patients use a mix — an IR dose first thing in the morning to get a quick “on” period, then CR for daytime smoothness, and an IR top-up before bed if needed.
Who Is Syndopa CR For?
Syndopa CR is appropriate for adults with idiopathic Parkinson disease who need symptomatic motor relief, including:
- Newly diagnosed patients in whom symptoms interfere with daily function (older patients especially — in younger patients, neurologists often start with a dopamine agonist or MAO-B inhibitor first to delay levodopa-related dyskinesia).
- Patients on a dopamine agonist or MAO-B inhibitor whose symptoms have progressed and who now need additional motor benefit.
- Patients experiencing end-of-dose “wearing-off” on standard immediate-release levodopa — the controlled-release matrix lengthens the duration of effect.
- Patients with overnight symptoms — a bedtime CR dose can reduce night-time stiffness and early-morning akinesia.
- Some patients with parkinsonism due to other causes (post-encephalitic, manganese intoxication, certain atypical syndromes) — under specialist guidance, with the understanding that response is usually less robust than in idiopathic PD.
Not appropriate for: patients with narrow-angle glaucoma, suspected melanoma or undiagnosed skin lesion, severe psychotic disorder, or current use of a non-selective MAO inhibitor (within 14 days).
Dosing and Administration
| Fază | Schedule | Note |
|---|---|---|
| Switching from IR to CR | Add 10–30% to the total daily levodopa dose; redistribute over 4–8 hours | CR is ~75% bioavailable |
| Typical schedule | 125 mg every 4–8 hours; 1–2 tablets per dose | Plus IR for first morning dose if needed |
| Bedtime dose | 125 mg or 250 mg at bedtime | Reduces overnight stiffness |
| Înghițiți întreagă | Do not crush or split (some scored CR formulations can be split into halves; check the tablet) | Crushing destroys the matrix |
Syndopa CR is the controlled-release formulation: onset is slower (45–90 minutes vs 30 for IR), peak is lower and later, duration is longer (5–7 hours per dose vs 3–5). This makes it well suited to maintaining steady plasma levels during the day and overnight, but less suitable for the first morning dose where rapid “on” is the priority — many advanced patients use IR for the first dose and CR for the rest of the day. Take ideally 30 minutes before food when possible; food (especially protein) delays and reduces absorption.
Long-Term Issues: Motor Fluctuations and Dyskinesia
After 5–10 years of levodopa therapy, many patients develop:
- Wearing-off — each dose lasts a shorter time; symptoms return before the next dose. Managed by shorter dose intervals, adding a COMT inhibitor (entacapone) or MAO-B inhibitor (rasagiline, safinamide).
- On–off phenomena — sudden unpredictable swings between mobile (“on”) and rigid (“off”) states.
- Dyskinesia — involuntary writhing or twisting movements at peak levodopa concentration. Managed by reducing each individual dose, adding amantadine, or changing the formulation.
- Freezing of gait — brief inability to start or continue walking. Less responsive to medication; physical-therapy strategies (visual cues, rhythmic music) often help more.
These problems are easier to delay than to treat once established — one reason younger patients are sometimes started on dopamine agonists or MAO-B inhibitors first.
Efecte Secundare Comune
Early in treatment: nausea, vomiting, anorexia, postural hypotension, dizziness, dry mouth. Most settle within 2–4 weeks. Taking with food or domperidone helps.
With long-term use: dyskinesia (peak-dose involuntary movements), motor fluctuations (wearing-off, on–off), hallucinations, vivid dreams, impulse-control disorders (less common than with dopamine agonists), insomnia, sudden-onset sleep, harmless reddish-brown discolouration of urine and sweat.
Mai puțin frecvente: confusion, paranoia, depression, mania, gambling/hypersexuality, neuroleptic malignant-like syndrome on abrupt withdrawal.
Drug and Food Interactions
- Non-selective MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) — contraindicated. Stop 14 days before starting levodopa.
- Dopamine antagonists — metoclopramide, prochlorperazine, haloperidol, risperidone, olanzapine: pharmacological antagonism. Use domperidone for nausea, quetiapine or clozapine for psychosis (under specialist care).
- Antihipertensive — additive postural hypotension.
- Iron salts — chelate levodopa in the gut. Separate doses by at least 2 hours.
- High-protein meals — large neutral amino acids compete for transport across the blood–brain barrier. Time doses 30 min before or 1 h after protein-rich food in fluctuating patients.
- Pyridoxine (vitamin B6) >10 mg/day — only relevant if levodopa is given without carbidopa. Combination products are protected.
Întrebări frecvente
Why is levodopa combined with carbidopa?
Carbidopa blocks the conversion of levodopa to dopamine in peripheral tissues, so far more reaches the brain. This reduces nausea, vomiting and blood-pressure drops, and lowers the effective levodopa dose by about 75%.
How is the CR formulation different from regular Syndopa?
CR uses a slow-dissolving matrix that releases levodopa over 4–6 hours rather than 1–2. Pros: smoother plasma levels, less wearing-off, useful at bedtime for overnight cover. Cons: slower onset (45–90 min vs 30 for IR), lower peak, food delays absorption more, bioavailability about 70–75% of IR. CR is rarely the only formulation a fluctuating patient uses — an IR “rescue” or first-morning dose often complements it.
Why does my urine turn dark on this medication?
Levodopa and its metabolites can give urine, sweat and saliva a harmless reddish-brown or rust colour. Some clothing stains may persist. This is not a sign of a kidney or liver problem and does not need investigation.
Can I take Syndopa CR with food?
In the first weeks, take with a small meal or snack to reduce nausea. Once on stable therapy, especially if you have wearing-off, take levodopa 30 min before or 1 h after a protein-rich meal — protein competes for absorption.
What is “wearing-off”?
After several years of levodopa therapy, each dose lasts a progressively shorter time and motor symptoms return before the next dose. This is wearing-off. It is managed by shorter dose intervals, adding a COMT inhibitor (entacapone) or MAO-B inhibitor (rasagiline, safinamide), or switching some doses to controlled-release.
What is “dyskinesia”?
Dyskinesia is involuntary writhing, twisting or rocking movement that occurs at the peak of the levodopa dose — the patient is “over-medicated” for that moment. It is managed by reducing each dose (and giving more frequent smaller doses), adding amantadine, or other strategies. Counterintuitively, it is a sign that the drug is working.
Can I stop Syndopa CR abruptly?
No. Sudden withdrawal can trigger a neuroleptic-malignant-like syndrome — fever, rigidity, confusion, autonomic instability. Tapering must be planned with your neurologist. If you cannot take it orally (e.g. surgery), ask about a rotigotine patch as a bridge.
Will Syndopa CR make me drowsy or cause “sleep attacks”?
Levodopa can cause daytime somnolence and, rarely, sudden-onset sleep without warning. Risk is higher when combined with a dopamine agonist. Until you know how you respond, do not drive long distances or operate heavy machinery.
Can Syndopa CR cause hallucinations or compulsive behaviours?
Yes — though both are more common with dopamine agonists than with levodopa. Visual hallucinations are most common, especially in older patients and those with cognitive impairment. New gambling, shopping, sexual or eating behaviours should be reported to your neurologist promptly. Reducing the dose or simplifying the regimen usually helps.
Can I take Syndopa CR during surgery or hospital admission?
Levodopa should ideally be continued through surgery. Tell the surgical team in advance. If you cannot swallow tablets, your team will arrange a feeding tube, transdermal rotigotine, or subcutaneous apomorphine. Do not let the drug be skipped for “NPO” reasons without a substitute — abrupt withdrawal is dangerous.
How does MedsBase ship Syndopa CR?
Worldwide shipping in discreet packaging from a WHO-GMP certified manufacturer. Tablets are shipped in original sealed blister packs. Track your order from your MedsBase account.
Depozitare
Store at room temperature (15–30°C / 59–86°F), protected from heat, moisture and direct light. Keep in the original container with the lid tightly closed. Keep out of reach of children. Do not use beyond the expiry date printed on the packaging.
Declinare de responsabilitate medicală
This information is provided for educational purposes only and is not a substitute for the advice of a qualified clinician. Parkinson disease and parkinsonian syndromes require individualised neurology care. Discuss all medications, supplements and pre-existing conditions with your doctor before starting, changing or stopping treatment. Do not abruptly discontinue dopaminergic therapy — sudden withdrawal can precipitate a neuroleptic malignant-like syndrome.
Alternative conexe
Alte produse din Afecțiuni cronice pe care clienții le vizualizează de asemenea:
More options in Parkinson's Disease Treatment
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Concentrație | 125 mg |
|---|---|
| Cantitate | 30 Comprimat/e, 60 Comprimat/e, 90 Comprimat/e, 180 Comprimat/e |
Syndopa CR
Întrebări și răspunsuri
Syndopa CR
Produse similare
Recenzii
Nu există recenzii încă